<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It is of general belief that males are prone to more frequent, more severe manifestations, and less favorable outcome </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated this hypothesis in ophthalmological manifestations (OM) of <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's Disease</z:e> (BD) </plain></SENT>
<SENT sid="2" pm="."><plain>Visual acuity (VA), <z:hpo ids='HP_0012122'>anterior uveitis</z:hpo>, <z:hpo ids='HP_0012123'>posterior uveitis</z:hpo> (PU), and <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> (RV) were checked, according to Ben Ezra, in 1,515 patients with eye lesions </plain></SENT>
<SENT sid="3" pm="."><plain>The data at baseline and last visit were compared </plain></SENT>
<SENT sid="4" pm="."><plain>Male/female ratio was 1.2 in the BD registry (6,500 patients) and 1.51 for OM patients (Chi(2) = 98.962, p &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>The patients-year-follow-up was 4,987 </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> parameters improved significantly from the baseline </plain></SENT>
<SENT sid="7" pm="."><plain>Mean VA improved from 4.87 to 5.35 for males (p &lt; 0.0001) and from 5.20 to 5.74 for females (p &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>Difference between males/females at baseline was not significant (p = 0.60) </plain></SENT>
<SENT sid="9" pm="."><plain>The mean improvement for males/females was statistically non-significant (p = 0.58) </plain></SENT>
<SENT sid="10" pm="."><plain>Percent improvement of eyes for males/females was 47.1%/48.8% (p = 0.41) </plain></SENT>
<SENT sid="11" pm="."><plain>Mean PU improved from 1.83 to 0.71 for males (p &lt; 0.0001) and from 1.66 to 0.49 for females (p &lt; 0.0001) </plain></SENT>
<SENT sid="12" pm="."><plain>Difference between males/females at baseline was significant (p = 0.01) </plain></SENT>
<SENT sid="13" pm="."><plain>The mean improvement for males/females was statistically non-significant (p = 0.45) </plain></SENT>
<SENT sid="14" pm="."><plain>Percent improvement of eyes for males/females was 75.4%/81.0% (p = 0.004) </plain></SENT>
<SENT sid="15" pm="."><plain>Mean RV improved from 2.05 to 1.16 for males (p &lt; 0.0001) and from 1.97 to 0.99 for females (p &lt; 0.0001) </plain></SENT>
<SENT sid="16" pm="."><plain>Difference between males/females at baseline was not significant (p = 0.42) </plain></SENT>
<SENT sid="17" pm="."><plain>The mean improvement for males/females was statistically non-significant (p = 0.47) </plain></SENT>
<SENT sid="18" pm="."><plain>Percent improvement of eyes for males/females was 62%/64.4% (p = 0.33) </plain></SENT>
<SENT sid="19" pm="."><plain>Male gender is more prone to ocular manifestations </plain></SENT>
<SENT sid="20" pm="."><plain>The severity of lesions at baseline was the same for VA and RV </plain></SENT>
<SENT sid="21" pm="."><plain>For PU, the difference was statistically significant, but was not clinically relevant </plain></SENT>
<SENT sid="22" pm="."><plain>The therapeutic outcome (mean improvement and percent of improved eyes) was the same for <z:hpo ids='HP_0000001'>all</z:hpo> parameters </plain></SENT>
</text></document>